logo
Share SHARE
FONT-SIZE Plus   Neg

Gilead's Sovaldi Shows Efficacy & Safety In Chronic Hepatitis C Patients

Gilead Sciences, Inc. (GILD) reported data from two Phase 2 studies and a compassionate access study, wherin a regimen containing once-daily Sovaldi 400 mg was administered to treat chronic hepatitis C virus or HCV infection in patients with advanced liver disease.

The first study, named Study GS-US-334-0125, is an ongoing open-label Phase 2 trial assessing HCV patients with cirrhosis and portal hypertension, with or without decompensation, who were randomized 1:1 to an immediate treatment arm in which Sovaldi and ribavirin or RBV was administered for 48 weeks or to a deferred treatment arm in which this regimen was started after a 24-week observation period.

Out of the 22 patients who completed 24 weeks of therapy, 95 percent achieved virologic suppression on treatment. Further, patients taking Sovaldi-based therapy experienced trends in clinical and laboratory parameter improvements compared to patients in the observation arm; and 80% of participants were treatment-experienced

Study GS-US-334-0126, was a single-arm open-label Phase 2 study in which patients with established recurrent HCV infection following liver transplantation received up to 24 weeks of therapy with Sovaldi plus RBV. The majority of patients had genotype 1-HCV infection and 88 percent were treatment-experienced. According to the company, seventy percent of patients in this study achieved SVR12.

by RTT Staff Writer

For comments and feedback: editorial@rttnews.com

Business News

Quick Facts

Editors Pick
Even after two years of thoroughly searching across the Indian Ocean, using modern technologies and devices, there is no clue about the Malaysian airline that vanished on March 8, 2014. Internet access is growing worldwide, but there is still a long way to go before the entire world is completely wired, a study from the Pew Research Center has found. The study also noted that men have greater access to the Internet than women in many nations. Backtracking on its early announcements on digital privacy, WhatsApp is planning to share member information, phone numbers and analytical data with Facebook, to make revenue from the platform.
comments powered by Disqus
Follow RTT